Nordic Entrepreneurship Magazine Covers Immunitrack’s COVID-19 Vaccine Efforts
In March of this year as the COVID-19 pandemic was rapidly taking hold worldwide, we joint forces with University of Copenhagen (Denmark) and Intavis (Germany) to identify novel candidate CD4 and CD8-stimulating epitopes from SARS-CoV-2 for vaccine development. Our CEO Stephan Thorgrimsen was recently interviewed by The Nordic Mentor Network for Entrepreneurship (NOME) about this work as well as our COVID-19 efforts since then.
Taking advantage of our unique in vitro NeoScreen® epitope immunogenicity prediction platform, we identified novel epitopes from SARS-CoV-2 that are anticipated to elicit a strong adaptive immune response, and we provided these results to the research community as a free resource for COVID-19 vaccine development. Our COVID-19 efforts have continued and we are now collaborating with researchers from Johns Hopkins University School of Medicine and the University of Southern Denmark to study how T cell responses to COVID-19 vary between patients with severe and mild symptoms. These studies will include patients from US and Danish hospitals and will allow us to assess the potential of the novel SARS-CoV-2 epitopes as well as help us to understand the kind of immune responses a vaccine needs to stimulate for effective clearance of SARS-CoV-2.
You can read NOME’s coverage of our COVID-19 work in their latest quarterly magazine here ▸ (just the article) or read the full magazine here ▸.
The Nordic Mentor Network for Entrepreneurship (NOME) is an elite Nordic Mentoring Programme for promising life science projects and startup companies. Immunitrack was one of the first 10 companies to join the NOME programme in 2017 and is today part of the NOME alumni. By matching Nordic companies with expert volunteer mentors that help them to realise their goals and technology milestones, NOME aims to transform Nordic-based life science startups into internationally renowned commercial success stories.
Immunitrack is a spinout from the academic group at University of Copenhagen, Denmark, that co-developed the widely used in silico MHC prediction tool, netMHC. Our mission is to provide the research community and the pharmaceutical industry with tools to select or redesign drug candidates during the early stages of R&D as well as to provide reagents to monitor the effects of lead drug candidates on patient immune responses.
Immunitrack actively collaborates with some of the leading research groups within immuno-oncology at the Johns Hopkins University Hospital, University of Columbia, Dana Farber Cancer Institute, and the National Center for Cancer Immune Therapy (see peer reviewed articles). We also partner with infectious disease experts at the University of Liverpool, most recently on the development of a Zika vaccine that is expected to reach the clinic within the next 12-18 months.
For further information, please contact:
Stephan Thorgrimsen, CEO